Page 19 - 《中国药房》2024年12期

（12）：1371-1379. Research Center for Atopic Dermatitis.Chinese guideline
[14] SIMPSON E L，SINCLAIR R，FORMAN S，et al. Effi‐ for diagnosis and treatment of atopic dermatitis：2020 edi‐
cacy and safety of abrocitinib in adults and adolescents tion[J]. Chin J Dermatol，2020，53（2）：81-88.
with moderate-to-severe atopic dermatitis（JADE MONO- [23] RADI G，SIMONETTI O，RIZZETTO G，et al. Barici‐
1）：a multicentre，double-blind，randomised，placebo- tinib：the first JAK inhibitor approved in Europe for the
controlled，phase 3 trial[J]. Lancet，2020，396（10246）： treatment of moderate to severe atopic dermatitis in adult
255-266. patients[J]. Healthcare，2021，9（11）：1575.
[15] SILVERBERG J I，SIMPSON E L，THYSSEN J P，et al. [24] MOHAMED M E F，TRUEMAN S，FENG T，et al. Cha-
Efficacy and safety of abrocitinib in patients with racterization of the effect of renal impairment on upadaci‐
moderate-to-severe atopic dermatitis：a randomized clini‐ tinib pharmacokinetics[J]. J Clin Pharmacol，2019，59（6）：
cal trial[J]. JAMA Dermatol，2020，156（8）：863-873. 856-862.
[16] BIEBER T，SIMPSON E L，SILVERBERG J I，et al. [25] TRUEMAN S，MOHAMED M F，FENG T，et al. Charac‐
Abrocitinib versus placebo or dupilumab for atopic derma‐ terization of the effect of hepatic impairment on upadaci‐
titis[J]. N Engl J Med，2021，384（12）：1101-1112. tinib pharmacokinetics[J]. J Clin Pharmacol，2019，59（9）：
[17] GUTTMAN-YASSKY E，SILVERBERG J I，NEMOTO 1188-1194.
O，et al. Baricitinib in adult patients with moderate-to- [26] WANG E Q，LE V，O’GORMAN M，et al. Effects of he‐
severe atopic dermatitis：a phase 2 parallel，double- patic impairment on the pharmacokinetics of abrocitinib
blinded， randomized placebo-controlled multiple-dose and its metabolites[J]. J Clin Pharmacol，2021，61（10）：
study[J]. J Am Acad Dermatol，2019，80（4）：913-921.e9. 1311-1323.
[18] REICH K，KABASHIMA K，PERIS K，et al. Efficacy and [27] WANG E Q，LE V，WINTON J A，et al. Effects of renal
safety of baricitinib combined with topical corticosteroids impairment on the pharmacokinetics of abrocitinib and its
for treatment of moderate to severe atopic dermatitis：a metabolites[J]. J Clin Pharmacol，2022，62（4）：505-519.
randomized clinical trial[J]. JAMA Dermatol，2020，156 [28] HOY S M. Baricitinib：a review in moderate to severe
（12）：1333-1343. atopic dermatitis[J]. Am J Clin Dermatol，2022，23（3）：
[19] SIMPSON E L，LACOUR J P，SPELMAN L，et al. Barici‐ 409-420.
tinib in patients with moderate-to-severe atopic dermatitis [29] SHAWKY A M，ALMALKI F A，ABDALLA A N，et al. A
and inadequate response to topical corticosteroids：results comprehensive overview of globally approved JAK inhibi‐
from two randomized monotherapy phase Ⅲ trials[J]. Br J tors[J]. Pharmaceutics，2022，14（5）：1001.
Dermatol，2020，183（2）：242-255. [30] SZALUS K，TRZECIAK M，NOWICKI R J. JAK-STAT
[20] BIEBER T，REICH K，PAUL C，et al. Efficacy and safety inhibitors in atopic dermatitis from pathogenesis to clini‐
of baricitinib in combination with topical corticosteroids cal trials results[J]. Microorganisms，2020，8（11）：1743.
in patients with moderate-to-severe atopic dermatitis with [31] DAVIS D M R，DRUCKER A M，ALIKHAN A，et al.
inadequate response，intolerance or contraindication to ci‐ Guidelines of care for the management of atopic dermati‐
closporin：results from a randomized，placebo-controlled， tis in adults with phototherapy and systemic therapies[J]. J
phase Ⅲ clinical trial（BREEZE-AD4）[J]. Br J Dermatol， Am Acad Dermatol，2024，90（2）：e43-e56.
2022，187（3）：338-352. [32] National Institute for Health and Care Excellence.Barici‐
[21] ROMERO JIMÉNEZ R M，HERRANZ PINTO P， tinib for treating moderate to severe atopic dermatitis[EB/
CAMPOS DOMÍNGUEZ M，et al. Cost-effectiveness OL].（2021-03-03）[2023-10-18]. www. nice. org. uk/gui-
analysis of abrocitinib compared with other systemic treat‐ dance/ta681.
ments for severe atopic dermatitis in Spain[J]. Pharmaco‐ [33] National Institute for Health and Care Excellence.Abroci‐
econ Open，2024，8（2）：291-302. tinib，tralokinumab or upadacitinib for treating moderate
[22] 中华医学会皮肤性病学分会免疫学组，特应性皮炎协作 to severe atopic dermatitis[EB/OL].（2022-08-03）[2023-
研究中心 . 中国特应性皮炎诊疗指南：2020 版[J]. 中华 10-18]. www.nice.org.uk/guidance/ta8141.
皮肤科杂志，2020，53（2）：81-88. （收稿日期：2023-12-27 修回日期：2024-03-09）
Immunology Group of the Dermatology and Venereology （编辑：舒安琴）
Branch of the Chinese Medical Association，Collaborative

中国药房 2024年第35卷第12期 China Pharmacy 2024 Vol. 35 No. 12 · 1425 ·